AbCellera Results Presentation Deck

Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 TECHNOLOGY DEVELOPMENT. VALUE OF PRE-PARTNERED PROGRAMS 2 YEARS OF TECH DEVELOPMENT 2 COVID ANTIBODY TREATMENTS 2.5M+ PATIENTS TREATED We had spent 2 years developing our technology specifically for pandemic response prior to the emergence of COVID-19 and initiated our work before entering into a partnership with Eli Lilly. Bamlanivimab was the first antibody to be authorized by FDA, and bebtelovimab continues to be used to combat the virus, remains effective against all known variants of concern, and is still the most potent COVID-19 antibody treatment available.

View entire presentation